244 related articles for article (PubMed ID: 35955749)
1. CD44 Contributes to the Regulation of MDR1 Protein and Doxorubicin Chemoresistance in Osteosarcoma.
Gerardo-Ramírez M; Keggenhoff FL; Giam V; Becker D; Groth M; Hartmann N; Straub BK; Morrison H; Galle PR; Marquardt JU; Herrlich P; Hartmann M
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955749
[TBL] [Abstract][Full Text] [Related]
2. Targeting CD44 by CRISPR-Cas9 in Multi-Drug Resistant Osteosarcoma Cells.
Xiao Z; Wan J; Nur AA; Dou P; Mankin H; Liu T; Ouyang Z
Cell Physiol Biochem; 2018; 51(4):1879-1893. PubMed ID: 30504723
[TBL] [Abstract][Full Text] [Related]
3. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.
Liu T; Li Z; Zhang Q; De Amorim Bernstein K; Lozano-Calderon S; Choy E; Hornicek FJ; Duan Z
Oncotarget; 2016 Dec; 7(50):83502-83513. PubMed ID: 27835872
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression.
Sugiu K; Tazawa H; Hasei J; Yamakawa Y; Omori T; Komatsubara T; Mochizuki Y; Kondo H; Osaki S; Fujiwara T; Yoshida A; Kunisada T; Ueda K; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Chemother Pharmacol; 2021 Sep; 88(3):513-524. PubMed ID: 34114067
[TBL] [Abstract][Full Text] [Related]
5. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
[TBL] [Abstract][Full Text] [Related]
6. Cluster of differentiation 44 promotes osteosarcoma progression in mice lacking the tumor suppressor Merlin.
Ma J; Klemm J; Gerardo-Ramírez M; Frappart L; Castven D; Becker D; Zoch A; Parent R; Bartosch B; Minnich K; Giovannini M; Danckwardt S; Hartmann N; Morrison H; Herrlich P; Marquardt JU; Hartmann M
Int J Cancer; 2020 Nov; 147(9):2564-2577. PubMed ID: 32525563
[TBL] [Abstract][Full Text] [Related]
7. Suppression of Estrogen Receptor Alpha Inhibits Cell Proliferation, Differentiation and Enhances the Chemosensitivity of P53-Positive U2OS Osteosarcoma Cell.
Wang JY; Chen CM; Chen CF; Wu PK; Chen WM
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681897
[TBL] [Abstract][Full Text] [Related]
8. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells.
Bourguignon LY; Peyrollier K; Xia W; Gilad E
J Biol Chem; 2008 Jun; 283(25):17635-51. PubMed ID: 18441325
[TBL] [Abstract][Full Text] [Related]
9. ABCG1 and Pgp identify drug resistant, self-renewing osteosarcoma cells.
Roundhill EA; Jabri S; Burchill SA
Cancer Lett; 2019 Jul; 453():142-157. PubMed ID: 30910588
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.
Gazzano E; Buondonno I; Marengo A; Rolando B; Chegaev K; Kopecka J; Saponara S; Sorge M; Hattinger CM; Gasco A; Fruttero R; Brancaccio M; Serra M; Stella B; Fattal E; Arpicco S; Riganti C
Cancer Lett; 2019 Aug; 456():29-39. PubMed ID: 31047947
[TBL] [Abstract][Full Text] [Related]
11. Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells.
Bourguignon LY; Spevak CC; Wong G; Xia W; Gilad E
J Biol Chem; 2009 Sep; 284(39):26533-46. PubMed ID: 19633292
[TBL] [Abstract][Full Text] [Related]
12. CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma.
Gao Y; Feng Y; Shen JK; Lin M; Choy E; Cote GM; Harmon DC; Mankin HJ; Hornicek FJ; Duan Z
Sci Rep; 2015 Jun; 5():11365. PubMed ID: 26079799
[TBL] [Abstract][Full Text] [Related]
13. A long non-coding RNA contributes to doxorubicin resistance of osteosarcoma.
Zhang CL; Zhu KP; Shen GQ; Zhu ZS
Tumour Biol; 2016 Feb; 37(2):2737-48. PubMed ID: 26408180
[TBL] [Abstract][Full Text] [Related]
14. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
Calcagno AM; Salcido CD; Gillet JP; Wu CP; Fostel JM; Mumau MD; Gottesman MM; Varticovski L; Ambudkar SV
J Natl Cancer Inst; 2010 Nov; 102(21):1637-52. PubMed ID: 20935265
[TBL] [Abstract][Full Text] [Related]
15. The Influence of MDR1 Expression Regulated by miR-138 through TRPS1 Signaling Pathway on Multidrug Resistance of Osteosarcoma and Formation of Bacterial Infection Biofilm.
Fang X; Zhu L; Wu Q; Zhong X; Chen Y; Zhu W
Cell Mol Biol (Noisy-le-grand); 2023 May; 69(5):51-57. PubMed ID: 37571901
[TBL] [Abstract][Full Text] [Related]
16. ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma.
Belisario DC; Akman M; Godel M; Campani V; Patrizio MP; Scotti L; Hattinger CM; De Rosa G; Donadelli M; Serra M; Kopecka J; Riganti C
Cells; 2020 Mar; 9(3):. PubMed ID: 32155954
[TBL] [Abstract][Full Text] [Related]
17. microRNA-143 is associated with the survival of ALDH1+CD133+ osteosarcoma cells and the chemoresistance of osteosarcoma.
Zhou J; Wu S; Chen Y; Zhao J; Zhang K; Wang J; Chen S
Exp Biol Med (Maywood); 2015 Jul; 240(7):867-75. PubMed ID: 25576341
[TBL] [Abstract][Full Text] [Related]
18. Inorganic phosphate enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin via a p53-dependent pathway.
Spina A; Sorvillo L; Di Maiolo F; Esposito A; D'Auria R; Di Gesto D; Chiosi E; Naviglio S
J Cell Physiol; 2013 Jan; 228(1):198-206. PubMed ID: 22674530
[TBL] [Abstract][Full Text] [Related]
19. Triggering of p73-dependent apoptosis in osteosarcoma is under the control of E2Fs-pRb2/p130 complexes.
La Sala D; Macaluso M; Trimarchi C; Giordano A; Cinti C
Oncogene; 2003 Jun; 22(23):3518-29. PubMed ID: 12789260
[TBL] [Abstract][Full Text] [Related]
20. Pioglitazone modulates doxorubicin resistance in a in vivo model of drug resistant osteosarcoma xenograft.
Natarajan A; Ramachandran B; Gopisetty G; Jayavelu S; Sundersingh S; Rajkumar T
Naunyn Schmiedebergs Arch Pharmacol; 2021 Feb; 394(2):361-371. PubMed ID: 33015747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]